To read the full story
Related Article
- Takeda CEO Weber to Retire Next Year, Succeeded by US Head
January 30, 2025
BUSINESS
- Taking on Solid Tumors - 2: Chugai Poised to Break through Solid Cancer “Wall” with Trispecific Antibodies
May 29, 2025
- Sawai, Fuso Ordered to Pay 20-Plus Billion Yen in Remitch Patent Suit
May 29, 2025
- Nothing Decided, Taiyo Says over Media Report on Buyout Proposals
May 29, 2025
- Kowa to Launch Japan PIII for Nicox-Partnered Glaucoma Drug
May 29, 2025
- China Approves Eisai’s Insomnia Med Dayvigo
May 28, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…